Severe pembrolizumab-associated neutropenia after CD34+ selected allogeneic hematopoietic-cell transplantation for multiple myeloma

Bone Marrow Transplant. 2018 Aug;53(8):1065-1068. doi: 10.1038/s41409-018-0142-4. Epub 2018 Mar 7.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / pharmacology
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antigens, CD34 / metabolism*
  • Antineoplastic Agents, Immunological / pharmacology
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Female
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Hematopoietic Stem Cell Transplantation / methods
  • Humans
  • Middle Aged
  • Multiple Myeloma / complications*
  • Multiple Myeloma / pathology
  • Neutropenia / etiology*
  • Neutropenia / pathology
  • Transplantation, Autologous / adverse effects*
  • Transplantation, Autologous / methods
  • Transplantation, Homologous / adverse effects*
  • Transplantation, Homologous / methods

Substances

  • Antibodies, Monoclonal, Humanized
  • Antigens, CD34
  • Antineoplastic Agents, Immunological
  • pembrolizumab